Table 2.

Overview of PML cases in patients receiving natalizumab.

n	Authors	Year	Gender	Age	Disease	Location	No. of doses	Study	Treatment regime	DMT before	Outcome
1	Van Asche et al.	2005	M	60	Crohn's	Europe	8	ENACT	Monotherapy	Aza, infliximab	Death
2	Langer-Gould et al.	2006	M	41	RRMS	USA	28	SENTINEL	Combination with Ifn-b	None	Severe Disability
3	Kleinschmidt et al.	2006	F	46	RRMS	USA	37	SENTINEL	Combination with Ifn-b	None Death
4	Biogen data1	2008	M	37	RRMS	Europe	17	Post-Marketing	Monotherapy	None Disabled∗
5	Biogen data1	2008	M	52	RRMS	Europe	14	Post-Marketing	Monotherapy Ifn-b, aza	Disabled∗	6	Biogen data2	2008	n.k.	n.k.	RRMS	USA	14	Post-Marketing	Monotherapy Ifn-b, ga, mtx	n.k.

Abbrevations: no. of doses, number of doses of natalizumab prior to first PML-symptoms; DMT, disease modifying therapy; RRMS, relapsing-remitting multiple sclerosis; aza, azathioprine; mtx, methotrexat; ga, glatiramer acetate; ifn-b, interferon-beta; ENACT, Evaluation of Natalizumab as Continuous Therapy in Crohn's disease.

¹Data presented by R. Gold at the World Congress on Therapy of Multiple Sclerosis in Montreal, Sep, 2008;

²Press release from Biogen Idec on 29 oct 2008;

^∗ current status; n.k., currently not known.